

REFERENCES

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 suppl):381S-453S.
2. Prevention of venous thromboembolism. In: Shojania KG, Duncan BW, McDonald KM, et al, eds. *Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco-Stanford Evidence-based Practice Center under Contract No. 290-97-0013), AHRQ Publication No. 01-E058, Rockville, MD: Agency for Healthcare Research and Quality. July 2001. Available at: <http://www.ahrq.gov/clinic/ptsafety/chap31a.htm>. Accessed August 11, 2009.
3. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA*. 2003;290:1868-1874.
4. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. *Br J Surg*. 1991;78:849-852.
5. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? *J R Soc Med*. 1989;82:203-205.
6. US Bureau of the Census. *Statistical Abstract of the United States: 2000*. 120th ed. Washington, DC: 2000.
7. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. *JAMA*. 2006;296:1858-1866.
8. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. 1999;353:1167-1173.
9. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. *Chest*. 1995;108:978-981.
10. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. *Ann Surg*. 2006;243:89-95.
11. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *Br J Surg*. 2001;88:913-930.
12. Michota F. Controversies and new directions in the management of venous thromboembolism in the perioperative setting. *Hospitalist*. 2004;6:S32-S38.
13. Centers for Medicare and Medicaid Services. CMS improves patient safety for Medicare and Medicaid by addressing never events. Available at: <http://www.cms.hhs.gov/apps/media/press/factsheet.asp?Counter=3224>. Accessed August 11, 2009.
14. Perez JV, Warwick DJ, Case CP, Bannister GC. Death after proximal femoral fracture—an autopsy study. *Injury*. 1995;26:237-240.
15. Freedman KB, Brookenthal KR, Fitzgerald RH, Jr, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg*. 2000;82-A:929-938.
16. Marigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*. 2000(3):CD001484.
17. Handoll HH, Farrar MJ, McBirnie J, et al. Heparin, low-molecular-weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. *Cochrane Database Syst Rev*. 2002(4):CD000305.
18. Stewart D, Zalamea N, Waxman K, et al. A prospective study of nurse and patient education on compliance with sequential compression devices. *Am Surg*. 2006;72:921-923.
19. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2007. Available at: http://www.aaos.org/research/guidelines/PE_guideline.pdf. Accessed August 5, 2009.
20. Hooker JA, Lachiewicz PF, Kelley SS, et al. Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. *J Bone Joint Surg Am*. 1999;81:690-696.
21. Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000;355:1295-1302.
22. Zurawska U, Parasuraman S, Goldhaber SZ. Prevention of pulmonary embolism in general surgery patients. *Circulation*. 2007;115:e302-e307.
23. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*. 2005;92:1212-1220.
24. Agnelli G, Piovello F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*. 1998;339:80-85.
25. Horlocker TT. What's a nice patient like you doing with a complication like this? Diagnosis, prognosis and prevention of spinal hematoma. *Can J Anaesth*. 2004;51:527-534.
26. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*. 2002;346:975-980.
27. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *J Thromb Haemost*. 2006;4:2384-2390.
28. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty. *Ann Int Med*. 2001;135:858-869.
29. Eriksson BI, Lassen MR. Duration of prophylaxis against VTE with fondaparinux (2.5 mg sc) after hip-fracture surgery. *Arch Int Med*. 2003;163:1337-1342.
30. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. *Lancet*. 2007;370:949-956.
31. Eriksson BI, Dahl OE, Rosencher N, Kurth AA. Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thrombosis Haemost*. 2007;5:2178-2185.
32. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358:2776-2786.
33. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358:2765-2775.
34. Tooyer R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. *Ann Surg*. 2005;241:397-415.
35. Nataloni R. Risk-assessment tool makes sure clots are prevented whenever possible. *ACP Hospitalist*. November 2008. Available at: <http://www.acphospitalist.org/archives/2008/11/tool.htm>. Accessed August 19, 2009.
36. Layer interventions. In: Maynard G, Stein J. *Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement*. AHRQ Publication No. 08-0075, August 2008. Agency for Healthcare Research and Quality, Rockville, MD. Available at: <http://www.ahrq.gov/qual/vtguidechap5.htm>. Accessed August 11, 2009.
37. McKenna GS, Karthikesalingam A, Walsh SR, et al. Prevention of venous thromboembolism: improving practice in surgical patients. *Int J Surg*. 2009;7:50-53.